Summary
67 / 100 · Bulios Score
What speaks for it
- Out of every 100 DKK of revenue, 22 DKK is left as free cash.
- It has been profitable 6 years in a row.
What to watch
- You pay 39.1 DKK for 1 DKK of yearly profit, a lot for its sector.
- Earnings per share fell by 10.0% a year over the last 3 years.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 39.1 DKK for 1 DKK of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (DKK)
Diluted EPS (DKK)
- Analyst estimate
Revenue grew by 8.5% a year over 5 years. Over the last 3 years it grew by 7.3% a year. For the next fiscal year analysts expect revenue to grow by 3.6%. Earnings per share fell by 10.0% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 DKK of revenue goes
- Cost of sales 42 DKK
- Research and development 3.6 DKK
- Sales and administration 29 DKK
- Taxes and other 17 DKK
- Net profit 9.7 DKK
Net profit, industry median (Medical - Instruments & Supplies) 8.1 DKK
Out of every 100 DKK of revenue, 9.7 DKK is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail